Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Exelixis, Inc. EXEL

Healthcare  —  Biotechnology
58.16 0.21 0.36% as of 25 Sep
Market cap
$14.4B
P/E
17.6×
Revenue Champion (10y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Exelixis, Inc. (EXEL) Business Profile

Updated before January 2025

Company Overview

Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company headquartered in Alameda, California, specializing in the discovery, development, and commercialization of new medicines to treat cancer. Founded in 1994 by Dr. Stelios Papadopoulos, Exelixis initially focused on genomics-based drug discovery. Over the years, the company has evolved into a leader in oncology therapeutics, with a strong emphasis on targeted therapies. The company’s mission is to improve the lives of cancer patients by delivering innovative therapies that address unmet medical needs.

Exelixis is led by a seasoned leadership team, including Michael M. Morrissey, Ph.D., who serves as the President and Chief Executive Officer. Dr. Morrissey has been instrumental in steering the company’s strategic direction and fostering its growth. Other key executives include Christopher J. Senner, Executive Vice President and Chief Financial Officer, and Peter Lamb, Ph.D., Executive Vice President and Chief Scientific Officer. Together, the leadership team has positioned Exelixis as a prominent player in the biotechnology sector.

Core Business Segments

Exelixis operates primarily in the oncology sector, focusing on the development and commercialization of therapies for cancer treatment. The company’s core business segments include:

1. Oncology Therapeutics

Exelixis is best known for its flagship product, CABOMETYX® (cabozantinib), a tyrosine kinase inhibitor (TKI) approved for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and other cancers. CABOMETYX has become a cornerstone of the company’s portfolio, generating significant revenue and establishing Exelixis as a leader in targeted cancer therapies.

Another key product is COMETRIQ® (cabozantinib), which is approved for the treatment of progressive, metastatic medullary thyroid cancer (MTC). While CABOMETYX and COMETRIQ share the same active ingredient, they are formulated differently to address distinct indications.

2. Pipeline Development

Exelixis has a robust pipeline of investigational therapies aimed at expanding its oncology portfolio. The company is actively exploring new indications for cabozantinib and developing novel compounds such as zanzalintinib (XL092), a next-generation TKI, and XB002, an antibody-drug conjugate (ADC) targeting tissue factor. These pipeline assets underscore Exelixis’s commitment to innovation and its focus on addressing unmet medical needs in oncology.

3. Partnerships and Collaborations

Exelixis has established strategic partnerships with leading pharmaceutical companies, including Ipsen, Takeda, and Roche, to expand the global reach of its products. These collaborations enable Exelixis to leverage the expertise and resources of its partners while focusing on its core competencies in drug discovery and development.

Business Model

Exelixis’s business model revolves around the discovery, development, and commercialization of innovative cancer therapies. The company generates revenue through product sales, milestone payments, and royalties from its partnerships. Key elements of its business model include:

  • Research and Development (R&D): Exelixis invests heavily in R&D to discover and develop new therapies. The company employs a rigorous, data-driven approach to identify promising drug candidates and advance them through clinical trials.
  • Commercialization: Exelixis has built a strong commercial infrastructure to support the launch and marketing of its products. The company’s sales and marketing efforts are focused on educating healthcare providers about the benefits of its therapies and ensuring patient access.
  • Partnerships: By collaborating with global pharmaceutical companies, Exelixis extends the reach of its products and shares the financial risks associated with drug development.

Strategic Direction

Exelixis is committed to advancing its mission of improving cancer care through innovation. The company’s strategic priorities include:

  • Expanding the CABOMETYX Franchise: Exelixis is conducting clinical trials to evaluate cabozantinib in combination with other therapies, such as immune checkpoint inhibitors, for additional cancer indications.
  • Advancing the Pipeline: The company is focused on progressing its next-generation TKIs and ADCs through clinical development, with the goal of bringing new therapies to market.
  • Global Expansion: Exelixis aims to increase its international presence by partnering with global pharmaceutical companies and pursuing regulatory approvals in new markets.
  • Sustainability: The company is committed to operating responsibly and minimizing its environmental impact. Exelixis has implemented initiatives to reduce energy consumption, waste, and greenhouse gas emissions.

Competitive Landscape

Exelixis operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Bristol-Myers Squibb (BMS): Known for its immuno-oncology therapies, such as Opdivo® and Yervoy®, BMS competes with Exelixis in the RCC and HCC markets.
  • Pfizer: With its oncology portfolio, including Sutent® and Inlyta®, Pfizer is a major competitor in the TKI space.
  • Merck & Co.: Merck’s Keytruda® is a leading immune checkpoint inhibitor that is often used in combination with TKIs for cancer treatment.
  • Roche: Roche’s focus on targeted therapies and diagnostics positions it as a competitor in the oncology market.

Risk Factors

Exelixis faces several risks that could impact its business, including:

  • Market Dependence: The company relies heavily on CABOMETYX for revenue generation. Any decline in sales or loss of market exclusivity could adversely affect its financial performance.
  • Regulatory Risks: The development and approval of new drugs are subject to stringent regulatory requirements. Delays or failures in obtaining approvals could hinder the company’s growth.
  • Competition: The oncology market is highly competitive, with numerous companies vying for market share. Exelixis must continuously innovate to maintain its competitive edge.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers for the production of its products. Any disruptions in the supply chain could impact product availability.

Recent Developments

Exelixis has made significant progress in advancing its pipeline and expanding its product portfolio. Recent developments include:

  • Clinical Trials: The company has initiated multiple clinical trials to evaluate cabozantinib in combination with other therapies for new cancer indications.
  • Pipeline Advancements: Exelixis is advancing its next-generation TKI, zanzalintinib, and its ADC, XB002, through clinical development.
  • Partnerships: The company has expanded its collaboration with Roche to explore new combination therapies.
  • Corporate Initiatives: Exelixis has implemented sustainability initiatives to reduce its environmental impact and promote corporate responsibility.

Investment Considerations

Investors considering Exelixis should weigh the following factors:

Strengths

  • Strong product portfolio led by CABOMETYX.
  • Robust pipeline with multiple investigational therapies.
  • Strategic partnerships with leading pharmaceutical companies.
  • Experienced leadership team with a proven track record.

Risks

  • Heavy reliance on CABOMETYX for revenue.
  • Intense competition in the oncology market.
  • Regulatory and clinical development risks.
  • Potential supply chain disruptions.

Conclusion

Exelixis, Inc. is a leading biotechnology company with a strong focus on oncology therapeutics. The company’s flagship product, CABOMETYX, and its robust pipeline position it for continued growth in the cancer treatment market. While Exelixis faces challenges such as market dependence and competition, its strategic initiatives and commitment to innovation provide a solid foundation for future success. As the company continues to expand its product portfolio and global presence, it remains well-positioned to deliver long-term value to patients and investors alike.